TORC - resTORbio, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
7.01
-0.01 (-0.13%)
As of 10:04AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close7.02
Open7.04
Bid6.99 x 1000
Ask7.07 x 800
Day's Range6.98 - 7.04
52 Week Range6.21 - 20.59
Volume51,685
Avg. Volume154,274
Market Cap247.182M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.42
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est29.00
Trade prices are not sourced from all markets
  • Zacks.com featured expert Kevin Matras highlights: Walker & Dunlop, Herc, ICICI Bank, HDFC Bank and resTORbio
    Zacks6 days ago

    Zacks.com featured expert Kevin Matras highlights: Walker & Dunlop, Herc, ICICI Bank, HDFC Bank and resTORbio

    Zacks.com featured expert Kevin Matras highlights: Walker & Dunlop, Herc, ICICI Bank, HDFC Bank and resTORbio

  • Buy These 5 Stocks as New Analysts Initiate Coverage
    Zacks7 days ago

    Buy These 5 Stocks as New Analysts Initiate Coverage

    Higher analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.

  • GlobeNewswire16 days ago

    resTORbio Announces Initiation of Phase 1b/2a Trial of RTB101 in Parkinson’s Disease

    BOSTON, April 02, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat age-related diseases, today announced the initiation of a Phase 1b/2a trial of RTB101, its orally administered, small molecule, potent inhibitor of target of rapamycin complex 1 (TORC1) product candidate, alone or in combination with sirolimus, in Parkinson’s disease (PD). “We believe that TORC1 may be an important therapeutic target for several neurodegenerative diseases associated with aging, in which misfolded proteins aggregate and cause neuronal toxicity. As such, we are excited to initiate our first clinical trial in PD and expand our pipeline into neurodegenerative disease,” said Chen Schor, Co-Founder, President and CEO of resTORbio.

  • GlobeNewswire27 days ago

    resTORbio, Inc. Announces Closing Public Offering of Common Stock

    BOSTON, March 22, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (“resTORbio” or the “Company”) (TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat age-related diseases, today announced the closing of its previously announced underwritten public offering of 7,200,000 shares of its common stock at a public offering price of $6.95 per share. The gross proceeds raised in the offering, before deducting underwriting discounts and commissions and offering expenses, are approximately $50.0 million, excluding any exercise of the underwriters’ option to purchase additional shares. BofA Merrill Lynch, SVB Leerink and Guggenheim Securities acted as joint book-running managers for the offering.

  • GlobeNewswirelast month

    resTORbio, Inc. Announces Pricing of Public Offering of Common Stock

    BOSTON, March 19, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (“resTORbio” or the “Company”) (TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat age-related diseases, today announced the pricing of an underwritten public offering of 7,200,000 shares of its common stock at a public offering price of $6.95 per share.

  • GlobeNewswirelast month

    resTORbio, Inc. Announces Proposed Public Offering of Common Stock

    BOSTON, March 18, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. ("resTORbio" or the "Company") (TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat age-related diseases, today announced that it has commenced an underwritten public offering of $50 million of shares of its common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. BofA Merrill Lynch, SVB Leerink and Guggenheim Securities are acting as joint book-running managers for the proposed offering.

  • GlobeNewswirelast month

    resTORbio Reports Fourth Quarter and Full Year 2018 Financial Results

    Positive End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA); Phase 3 program of RTB101 expected to initiate in 2Q19 Phase 1b/2a trial of RTB101 in.

  • GlobeNewswirelast month

    resTORbio Announces Positive End-of-Phase 2 Meeting with FDA and Planned Initiation of Global Phase 3 Program for RTB101

    BOSTON, March 18, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat age-related diseases, today announced plans to initiate its Phase 3 program of RTB101 10 mg once daily following its End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA). The Phase 3 program will evaluate whether RTB101 decreases, as compared to placebo, the percentage of subjects with clinical symptoms consistent with a respiratory tract infection (RTI) with or without laboratory-confirmation of a pathogen. "Our collaborative interactions with the FDA have us on track to start our Phase 3 program and advance RTB101 towards the potential submission of a New Drug Application (NDA).

  • GlobeNewswire2 months ago

    resTORbio to Present at 8th Annual SVB Leerink Global Healthcare Conference

    BOSTON, Feb. 21, 2019 -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing a new class of medicines that target the biology of aging to.

  • GlobeNewswire2 months ago

    resTORbio Appoints Erkan Baloglu, Ph.D., M.B.A., as Vice President of Drug Discovery and Medicinal Chemistry

    BOSTON, Feb. 06, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (TORC), a clinical-stage biopharmaceutical company developing a new class of medicines that target the biology of aging to prevent or treat age-related diseases, today announced the appointment of Erkan Baloglu, Ph.D., M.B.A., as Vice President, Drug Discovery and Medicinal Chemistry. “We are pleased to welcome Erkan to resTORbio, as we continue to expand our team in anticipation of building out our pipeline of novel therapeutics for the treatment of aging-related diseases,” said Chen Schor, Co-Founder, President and CEO of resTORbio.

  • GlobeNewswire3 months ago

    resTORbio to Host Key Opinion Leader Symposium on TORC1 Inhibition and Neurodegenerative Disease

    BOSTON, Jan. 31, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (TORC), a clinical-stage biopharmaceutical company developing a new class of medicines that target the biology of aging to prevent or treat age-related diseases, today announced it will host a key opinion leader (KOL) symposium on the potential of TORC1 inhibition to ameliorate neurodegenerative disease, with a focus on Parkinson’s disease, on Thursday, February 7, 2019 at 8:30 a.m. ET in New York, NY.

  • GlobeNewswire4 months ago

    resTORbio Appoints William Marshall, M.D., as Vice President of Medical Sciences

    BOSTON, Dec. 19, 2018 (GLOBE NEWSWIRE) -- resTORbio, Inc. (TORC), a clinical-stage biopharmaceutical company focused on helping people live healthier longer through the development and commercialization of novel therapeutics for the treatment of aging-related diseases, today announced the appointment of William Marshall, M.D., as Vice President of Medical Sciences at resTORbio. “We are incredibly excited to have Bill join resTORbio as we continue to build out our team in anticipation of initiating our Phase 3 program to reduce the incidence of respiratory tract infections in high-risk elderly and our Phase 2 program in Parkinson’s disease,” said Chen Schor, Co-Founder, President and CEO of resTORbio.

  • GlobeNewswire5 months ago

    resTORbio Reports Third Quarter 2018 Financial Results

    Additional positive data from Phase 2b trial further support RTB101’s potential in reducing the incidence of respiratory tract infections (RTIs) in high-risk elderly patients.

  • GlobeNewswire5 months ago

    resTORbio Co-Founder and Chief Medical Officer Joan Mannick, M.D., to Present on TORC1 Inhibition at The Gerontological Society of America 2018 Annual Scientific Meeting

    BOSTON, Nov. 08, 2018 (GLOBE NEWSWIRE) -- resTORbio, Inc. (TORC), a clinical-stage biopharmaceutical company focused on helping people live healthier longer through the development and commercialization of novel therapeutics for the treatment of aging-related diseases, today announced that Joan Mannick, M.D., Co-Founder and Chief Medical Officer, will present at The Gerontological Society of America 2018 Annual Scientific Meeting (GSA 2018), November 14-18, 2018, in Boston. Dr. Mannick will deliver an oral presentation during a symposium session as part of the GSA 2018 Biological Sciences Program, which includes symposia and poster sessions focusing on the aging process at the molecular, cellular and organismal level and disease conditions related to or accompanying the aging process.

  • GlobeNewswire5 months ago

    resTORbio to Present at Upcoming Investor Conferences in November

    BOSTON, Nov. 07, 2018 -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company focused on helping people live healthier longer through the development and.

  • GlobeNewswire5 months ago

    resTORbio Appoints Michael Grissinger to its Board of Directors

    BOSTON, Nov. 06, 2018 (GLOBE NEWSWIRE) -- resTORbio, Inc. (TORC), a clinical-stage biopharmaceutical company focused on helping people live healthier longer through the development and commercialization of novel therapeutics for the treatment of aging-related diseases, today announced the appointment of Michael Grissinger to its Board of Directors. “Michael Grissinger brings significant pharma experience to our Board of Directors.

  • ResTORbio (TORC) Continue to Surge Higher?
    Zacks9 months ago

    ResTORbio (TORC) Continue to Surge Higher?

    As of late, it has definitely been a great time to be an investor in resTORbio, Inc. (TORC)

  • 3 Healthcare Stocks That Skyrocketed 35% or More This Week: Are They Still Buys?
    Motley Fool9 months ago

    3 Healthcare Stocks That Skyrocketed 35% or More This Week: Are They Still Buys?

    These stocks jumped much higher over the last few days. But should investors jump on the bandwagon?